接受生长激素治疗患者的白血病。

Leukemia in a patient treated with growth hormone.

作者信息

Aktan M, Tanakol R, Nalçaci M, Dinçol G

机构信息

Division of Hematology, Istanbul Medical School, University of Istanbul, Capa, Turkey.

出版信息

Endocr J. 2000 Aug;47(4):471-3. doi: 10.1507/endocrj.47.471.

DOI:10.1507/endocrj.47.471

PMID:11075729

Abstract

It is well known that growth hormone (GH) therapy is associated with increased risk of development of malignant tumors, especially leukemia. In the case presented, growth hormone treatment was initiated in a 25-year-old patient with hypopituitarism. After 4 months of therapy with thrice a week injections of rhGH, acute myelogenous leukemia developed. It was thought that no clearcut evidence existed to establish a relationship between the growth hormone treatment and development of acute leukemia.

摘要

众所周知，生长激素（GH）治疗与恶性肿瘤尤其是白血病的发生风险增加有关。在本文所述病例中，一名25岁的垂体功能减退患者开始接受生长激素治疗。在每周三次注射重组人生长激素（rhGH）治疗4个月后，患者患上了急性髓性白血病。当时认为，尚无明确证据证实生长激素治疗与急性白血病的发生之间存在关联。